Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Ovarian Cancer Pipeline Review: Sponsors Plan Frontline Punch, Smart Combinations

Dec 07 2018

• By Emily Hayes

Ovarian cancer

Related Content

Stellar Survival Data For AZ's Lynparza Hailed At ESMO

Oct 22 2018

FDA Finally Approves Avastin In First-Line Ovarian Cancer

Jun 13 2018

Tesaro's Zejula Expansion Includes Keytruda Combo, Lung Cancer

Jun 05 2017

Immuno-Oncology Outlook: Bavencio Leads PD-1/L1 Pack In Ovarian Cancer

Jul 18 2017

The PARP Combo Race Is On: Clovis And Bristol Partner On Rubraca

Jul 31 2017

AZ's Lynparza PARP Lead Likely To Lengthen With FDA Priority Review

Nov 12 2018

Clovis Transitions To Commercial Stage On Rubraca Approval

Dec 20 2016

Related Companies

AstraZeneca PLC

Merck & Co., Inc.

Roche Holding AG

Clovis Oncology, Inc.

Bristol Myers Squibb Company

Tesaro, Inc.

ImmunoGen, Inc.

GSK plc

Additional Topics

Commercial ImmunoOncology Market Snapshot Cancer BioPharmaceutical

More from Business

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window